|
US9732131B2
(en)
|
2006-02-27 |
2017-08-15 |
Calviri, Inc. |
Identification and use of novopeptides for the treatment of cancer
|
|
US20170313775A1
(en)
|
2014-11-13 |
2017-11-02 |
The Johns Hopkins University |
Checkpoint Blockade and Microsatellite Instability
|
|
MA40737A
(fr)
|
2014-11-21 |
2017-07-04 |
Memorial Sloan Kettering Cancer Center |
Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
|
|
WO2016146143A1
(en)
|
2015-03-16 |
2016-09-22 |
Amal Therapeutics Sa |
Cell penetrating peptides and complexes comprising the same
|
|
US20190099475A1
(en)
|
2015-04-08 |
2019-04-04 |
Nantomics, Llc |
Cancer neoepitopes
|
|
JP7236216B2
(ja)
*
|
2015-04-23 |
2023-03-09 |
ナントミクス，エルエルシー |
がんのネオエピトープ
|
|
EP3294324A1
(en)
|
2015-05-13 |
2018-03-21 |
Agenus Inc. |
Vaccines for treatment and prevention of cancer
|
|
GB201516047D0
(en)
*
|
2015-09-10 |
2015-10-28 |
Cancer Rec Tech Ltd |
Method
|
|
KR20180083327A
(ko)
*
|
2015-10-12 |
2018-07-20 |
난토믹스, 엘엘씨 |
바이러스성 암 네오에피토프를 위한 조성물 및 방법
|
|
EP3362929B1
(en)
*
|
2015-10-12 |
2020-08-12 |
Nantomics, LLC |
Viral neoepitopes and uses thereof
|
|
JP2018532736A
(ja)
*
|
2015-10-12 |
2018-11-08 |
ナントミクス，エルエルシー |
チェックポイント阻害物質への感受性を予測するｍｓｉおよびネオエピトープの探索のための系、組成物、および方法
|
|
EP3719143B1
(en)
*
|
2015-10-23 |
2023-07-26 |
Novartis AG |
Method of deriving a value for percent biomarker positivity for selected cells present in a field of view
|
|
TWI733719B
(zh)
|
2015-12-07 |
2021-07-21 |
美商河谷控股Ｉｐ有限責任公司 |
改善的組合物及用於新表位之病毒遞送的方法及其應用
|
|
US20170199961A1
(en)
|
2015-12-16 |
2017-07-13 |
Gritstone Oncology, Inc. |
Neoantigen Identification, Manufacture, and Use
|
|
CN108472350A
(zh)
*
|
2016-01-08 |
2018-08-31 |
瓦西博迪公司 |
新表位rna癌症疫苗
|
|
KR20180107257A
(ko)
|
2016-02-19 |
2018-10-01 |
난트 홀딩스 아이피, 엘엘씨 |
면역원 조절 방법 (methods of immunogenic modulation)
|
|
KR102500659B1
(ko)
|
2016-02-29 |
2023-02-16 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
WO2017151517A1
(en)
*
|
2016-02-29 |
2017-09-08 |
Foundation Medicine, Inc. |
Methods of treating cancer
|
|
JP6710004B2
(ja)
*
|
2016-03-15 |
2020-06-17 |
Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 |
免疫療法のためのモニタリングまたは診断ならびに治療剤の設計
|
|
LT3429618T
(lt)
*
|
2016-03-16 |
2024-05-10 |
Amal Therapeutics Sa |
Imuninės sistemos patikros taško moduliatoriaus ir komplekso, apimančio į ląsteles prasiskverbiantį peptidą, krovinį ir tlr peptido agonistą, derinys, skirtas naudoti medicinoje
|
|
JP2019517557A
(ja)
*
|
2016-06-10 |
2019-06-24 |
アイオー セラピューティクス インコーポレイテッド |
癌免疫療法のための受容体選択的レチノイドおよびレキシノイド化合物および免疫調節因子
|
|
US20190247435A1
(en)
*
|
2016-06-29 |
2019-08-15 |
The Johns Hopkins University |
Neoantigens as targets for immunotherapy
|
|
WO2018055060A1
(en)
|
2016-09-21 |
2018-03-29 |
Amal Therapeutics Sa |
Fusion comprising a cell penetrating peptide, a multi epitope and a tlr peptide agonist for treatment of cancer
|
|
EP3516081A4
(en)
*
|
2016-09-23 |
2020-07-29 |
Memorial Sloan Kettering Cancer Center |
DETERMINANTS OF CANCER RESPONSE TO IMMUNOTHERAPY
|
|
IL265759B2
(en)
*
|
2016-10-06 |
2025-10-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer
|
|
WO2018102613A2
(en)
|
2016-12-01 |
2018-06-07 |
Nantomics, Llc |
Tumor antigenicity processing and presentation
|
|
WO2018112449A2
(en)
|
2016-12-16 |
2018-06-21 |
Nant Holdings Ip, Llc |
Live cell imaging systems and methods to validate triggering of immune response
|
|
WO2018132753A1
(en)
*
|
2017-01-13 |
2018-07-19 |
Nantbio, Inc. |
Validation of neoepitope-based treatment
|
|
ES2971298T3
(es)
|
2017-01-18 |
2024-06-04 |
Icahn School Med Mount Sinai |
Neoantígenos y usos de los mismos para el tratamiento del cáncer
|
|
WO2018146128A1
(en)
*
|
2017-02-07 |
2018-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy
|
|
CA3056700A1
(en)
*
|
2017-03-17 |
2018-09-20 |
Nantomics, Llc |
Liquid biopsy for cfrna
|
|
IL269026B2
(en)
*
|
2017-03-31 |
2024-12-01 |
Bristol Myers Squibb Co |
Anti-pd-1 antibodies for treating tumors in high tumor mutational burden (tmb) patients
|
|
WO2018222433A2
(en)
|
2017-05-30 |
2018-12-06 |
Nant Holdings Ip, Llc |
Circulating tumor cell enrichment using neoepitopes
|
|
CN110996970A
(zh)
|
2017-06-02 |
2020-04-10 |
亚利桑那州立大学董事会 |
创建个性化癌症疫苗的方法
|
|
US10311967B2
(en)
*
|
2017-06-13 |
2019-06-04 |
Bostongene Corporation |
Systems and methods for generating, visualizing and classifying molecular functional profiles
|
|
GB201710815D0
(en)
*
|
2017-07-05 |
2017-08-16 |
Francis Crick Inst Ltd |
Method
|
|
WO2019055618A1
(en)
|
2017-09-15 |
2019-03-21 |
Arizona Board Of Regents On Behalf Of Arizona State University |
METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
|
|
KR20200059243A
(ko)
|
2017-09-20 |
2020-05-28 |
리제너론 파마슈티칼스 인코포레이티드 |
패신저 유전자 돌연변이 부담이 높은 종양을 가진 환자에 대한 면역 치료요법
|
|
EP4226944A3
(en)
*
|
2017-09-25 |
2023-10-25 |
Memorial Sloan Kettering Cancer Center |
Tumor mutational load and checkpoint immunotherapy
|
|
EP3688165A4
(en)
|
2017-09-25 |
2021-09-29 |
Nant Holdings IP, LLC |
VALIDATION OF THE PRESENTATION OF NEOEPITOPES
|
|
ES3029080T3
(en)
|
2017-10-10 |
2025-06-23 |
Seattle Project Corp |
Neoantigen identification using hotspots
|
|
KR20200064132A
(ko)
|
2017-10-15 |
2020-06-05 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
EP3704268B1
(en)
|
2017-11-03 |
2025-01-22 |
Guardant Health, Inc. |
Normalizing tumor mutation burden
|
|
JP2021503077A
(ja)
*
|
2017-11-09 |
2021-02-04 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
細胞外小胞タンパク質、ならびに癌診断、療法に対する応答予測、および治療をするためのそれらの使用
|
|
US11885815B2
(en)
|
2017-11-22 |
2024-01-30 |
Gritstone Bio, Inc. |
Reducing junction epitope presentation for neoantigens
|
|
AU2018375008B2
(en)
|
2017-12-01 |
2024-06-27 |
Illumina, Inc. |
Methods and systems for determining somatic mutation clonality
|
|
CN108009400B
(zh)
*
|
2018-01-11 |
2018-07-06 |
至本医疗科技（上海）有限公司 |
全基因组肿瘤突变负荷预测方法、设备以及存储介质
|
|
US11414698B2
(en)
*
|
2018-03-22 |
2022-08-16 |
Chang Gung Medical Foundation Chang Gung Memorial Hospital At Chiayi |
Method of quantifying mutant allele burden of target gene
|
|
US11065317B2
(en)
|
2018-04-26 |
2021-07-20 |
Agenus Inc. |
Heat shock protein-binding peptide compositions and methods of use thereof
|
|
CN120193081A
(zh)
|
2018-07-23 |
2025-06-24 |
夸登特健康公司 |
用于通过肿瘤分数和覆盖率调整肿瘤突变负荷的方法和系统
|
|
CN121354685A
(zh)
|
2018-08-31 |
2026-01-16 |
夸登特健康公司 |
无细胞dna中的微卫星不稳定性检测
|
|
CN109371005B
(zh)
*
|
2018-11-12 |
2022-09-30 |
上海市东方医院（同济大学附属东方医院） |
一种hla-0201限制性padi4表位多肽及其应用
|
|
EP3893932A4
(en)
*
|
2018-12-12 |
2022-09-07 |
Medimmune, LLC |
BLOOD-BASED TUMORMUTATION LOAD AS A PREDICTOR OF OVERALL SURVIVAL IN NON-SMALL CELL LUNG CANCER
|
|
US20220081723A1
(en)
*
|
2018-12-21 |
2022-03-17 |
Agency For Science, Technology And Research |
Method of predicting for benefit from immune checkpoint inhibition therapy
|
|
WO2020206127A1
(en)
*
|
2019-04-05 |
2020-10-08 |
Illumina, Inc. |
Quantitative score of hla diversity
|
|
CN114245874A
(zh)
*
|
2019-05-24 |
2022-03-25 |
艾迪菲斯健康有限公司 |
用于癌症免疫疗法的精准医学方法
|
|
WO2021067550A1
(en)
|
2019-10-02 |
2021-04-08 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods and compositions for identifying neoantigens for use in treating and preventing cancer
|
|
NL2024107B1
(en)
*
|
2019-10-26 |
2021-07-19 |
Vitroscan B V |
Compositions for Patient Specific Immunotherapy
|
|
CN111088349B
(zh)
*
|
2020-02-14 |
2023-04-28 |
深圳市宝安区妇幼保健院 |
Kir3dl1基因分型引物组及其应用
|
|
US20230108284A1
(en)
*
|
2020-03-23 |
2023-04-06 |
Koninklijke Philips N.V. |
Prediction of radiotherapy response for prostate cancer subject based on immune checkpoint genes
|
|
GB202007099D0
(en)
|
2020-05-14 |
2020-07-01 |
Kymab Ltd |
Tumour biomarkers for immunotherapy
|
|
WO2022009052A2
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
EP4000596A1
(en)
*
|
2020-11-17 |
2022-05-25 |
The Boots Company plc |
Tetrapeptide and compositions comprising tetrapeptides
|
|
EP4000595A1
(en)
*
|
2020-11-17 |
2022-05-25 |
The Boots Company plc |
Tetrapeptide and compositions comprising tetrapeptides
|
|
US20240192195A1
(en)
*
|
2021-04-10 |
2024-06-13 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
A multiomic approach to modeling of gene regulatory networks in multiple myeloma
|
|
AU2021461416A1
(en)
|
2021-08-24 |
2024-02-22 |
BioNTech SE |
In vitro transcription technologies
|
|
WO2024083345A1
(en)
|
2022-10-21 |
2024-04-25 |
BioNTech SE |
Methods and uses associated with liquid compositions
|
|
WO2024216165A1
(en)
|
2023-04-12 |
2024-10-17 |
Icahn School Of Medicine At Mount Sinai |
Computational methods for selecting personalized neoantigen vaccines
|